haematological malignancy
Bristol Myers Squibb’s New Drug Application for mezigdomide accepted by FDA
Mezigdomide improves progression-free survival in patients with relapsed or refractory multiple myeloma
Legend Biotech appoints new group of scientific advisors
The company is focused on CAR-T cell therapy to treat multiple myeloma
Bristol Myers Squibb evolves and expands multiple myeloma programme
Created in 2016, the Standing in the Gaap programme aims to advance more equitable care
Gilead to acquire Arcellx in deal worth $7.8bn
The US FDA has accepted a licence application for drug for relapsed/refractory multiple myeloma
Johnson & Johnson’s Darzalex Faspro regimen receives FDA approval for multiple myeloma
Multiple myeloma has an average five-year survival rate of 59.8% and is currently incurable
J&J receives positive NICE recommendation for multiple myeloma treatment
The treatment is approved for use within the NHS in England and Wales
Johnson & Jonson secures FDA approval for multiple myeloma treatment
Support for first and only high-risk smouldering multiple myeloma treatment came from positive phase 3 trial results
GSK’s Blenrep approved by FDA for multiple myeloma
Approval supported by positive results from phase 3 trial
Sanofi’s multiple myeloma candidate granted FDA orphan drug designation
More than 180,000 people worldwide are diagnosed with the disease every year
Sanofi’s Sarclisa approved by EC to treat newly diagnosed multiple myeloma
The drug is already approved in the EU across three other multiple myeloma indications
GSK’s Blenrep combinations granted EC approval for relapsed/refractory multiple myeloma
More than 50,000 cases of the blood cancer are diagnosed in Europe each year
Johnson & Johnson’s Darzalex approved by EC as first treatment for high-risk SMM
The early precursor of active multiple myeloma accounts for around 15% of all new multiple myeloma cases